Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 5, keine Gesamtzahl für „lenvatinib“
Suchtreffer
Begriffe & Kennungen
Lenvima · 4.8 · In the Phase 3 Study 309 (see section 5.1), proteinuria was reported in 29.6% of lenvatinib plus pembrolizumab
Eintrag öffnenLenvima · 4.8 · In the Phase 3 Study 309 (see section 5.1), there was one event of PRES (Grade 1) in the lenvatinib plus pembr
Eintrag öffnenLenvima · 4.8 · In the paediatric Studies 207, 216, 230, and 231 (see section 5.1), the overall safety profile of lenvatinib a
Eintrag öffnenLenvima · 4.8 · In the pivotal Phase 3 SELECT trial (see section 5.1), hypocalcaemia was reported in 12.6% of lenvatinib-treat
Eintrag öffnenLenvima · 4.8 · In the pivotal Phase 3 SELECT trial (see section 5.1), proteinuria was reported in 33.7% of lenvatinib- treate
Eintrag öffnenLenvima · 4.8 · In the pivotal Phase 3 SELECT trial (see section 5.1), there was 1 event of PRES (Grade 2) in the lenvatinib-t
Eintrag öffnenLenvima · 4.8 · Lenvatinib use has been associated with cases of fistulae including reactions resulting in death. Reports of f
Eintrag öffnenLenvima · 4.8 · System Organ Class Lenvatinib monotherapy Combination with pembrolizumab (MedDRA terminology) Cardiac disorder
Eintrag öffnenLenvima · 4.8 · System Organ Class Lenvatinib monotherapy Combination with pembrolizumab (MedDRA terminology) General disorder
Eintrag öffnenLenvima · 4.8 · System Organ Class Lenvatinib monotherapy Combination with pembrolizumab (MedDRA terminology) Hepatobiliary di
Eintrag öffnenLenvima · 4.8 · System Organ Class Lenvatinib monotherapy Combination with pembrolizumab (MedDRA terminology) Infections and i
Eintrag öffnenLenvima · 4.8 · Table 6 Adverse reactions reported in patients treated with lenvatinib§
Eintrag öffnenLenvima · 4.8 · The median time to first onset in lenvatinib-treated patients was 10.1 weeks. No differences between lenvatini
Eintrag öffnenLenvima · 4.8 · The safety of lenvatinib in combination with pembrolizumab has been evaluated in 530 patients with advanced EC
Eintrag öffnenLenvima · 4.8 · The safety profile of lenvatinib as combination therapy is based on data from 530 EC patients treated with len
Eintrag öffnenLenvima · 4.8 · The safety profile of lenvatinib as monotherapy is based on data from 452 DTC patients and 496 HCC patients; a
Eintrag öffnenlenvatinib
Eintrag öffnenlenvatinib mesilate
Eintrag öffnenlenvatinib mesilate
Eintrag öffnenlenvatinib mesylate
Eintrag öffnen